Eligibility for GLP-1 RA therapy for weight management was defined as: (1) BMI 30 kg/m 2 , or (2) BMI 2729.9 kg/m 2 with at least one documented weight-related comorbidity (arterial hypertension, coronary artery disease, hypercholesterolemia, or sleep apnea)
This further puts patients at risk for loss of appetite and insufficient nutritional intake
(2024) have identified close association between dysregulated fluctuations in sex steroid hormone levels, such as prolactin and testosterone, and the pathophysiology of EDC
Liposomal delivery bypasses digestion, potentially offering better absorption than standard oral glutathione supplements
PT-141 (bremelanotide) is a more selective central MC4R agonist that acts in the brain to increase sexual desire and arousal, rather than acting on the genital vasculature like PDE5 inhibitors [1] [3]